# Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. ENAMINE US INC

Federal contract opportunity, via Kontrakk.

- **Agency:** HEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH.NATIONAL INSTITUTES OF HEALTH OLAO
- **Notice ID:** cda237d603a841e58a64dfcb661f51e2
- **Solicitation number:** 75N98026Q01193ENAMINEUSINCPCANIAAA08396
- **Notice type:** Combined Synopsis/Solicitation
- **Set-aside:** No Set aside used
- **NAICS:** 424690
- **Place of performance:** Bethesda, MD
- **Posted:** September 10, 2026
- **Response deadline:** September 19, 2026
- **View on Kontrakk:** https://kontrakk.com/contracts/cda237d603a841e58a64dfcb661f51e2
- **View on SAM.gov:** https://sam.gov/workspace/contract/opp/cda237d603a841e58a64dfcb661f51e2/view

## Description

The Section on Medicinal Chemistry (SMC) develops new molecular entities with implications in improving health and treatment for various metabolic and alcohol associated diseases. To assess the translational potential of novel molecular entities, which would allow us to make decisions to proceed the compounds for further development we utilize multiple derisking assays. These assays comprise of both cell-based (in vitro) testing and then eventually in mice to assess pharmacokinetic parameters to see if the drug is orally available. 

Request to procure Chemical Reagent (Assay) Development & Laboratory Testing Service SMC to produce grouped ADME assays and perform a Pharmacokinetic study in C57BL6 mice. By including the Caco-2 Permeability Assay in our ADME evaluation it'll accurately predict the oral absorption potential of our compounds. This well-established in vitro model closely mimics the human intestinal epithelium, providing critical insights into a compound’s passive diffusion, active transport, and efflux processes, such as those mediated by P-glycoprotein (P-gp). The data generated from this assay are vital for informing structure-activity relationship (SAR) optimization, improving compound permeability, and reducing transporter-related liabilities that could hinder bioavailability

## Points of contact

- Vishnuvajjala Hanumanth Rao · vishnuh@mail.nih.gov (primary)